Quantify Research has supported the Swedish Association of the Pharmaceutical Industry (LIF) to re-analyse the EFPIA 2017 Patients W.A.I.T. Indicator for new medicines. We found that about 1/3 of EMA approved medicines are not available in Sweden. Some of these can be replaced with other treatment options, but in other cases Swedish patients may suffer consequences from not having access to the latest medicines available for their disease. For available medicines the average time to market was 10 months.

More information about the report can be found here.